Dosage

Ivermectin Dosage represents the quantitative, weight-adjusted administration schedules (typically 150–200 mcg/kg for approved human indications) and timing parameters calibrated to achieve therapeutic blood serum concentrations while minimizing neurotoxic and gastrointestinal risks.

Foundational Clinical Guides (Start Here)

Dosing & Administration Guide

Do you take ivermectin with food? Maximize Effectiveness and Minimize Risks

Clinical analysis and evidence-based reference guide covering indications, administration protocols, and safety parameters.

Dosing & Administration Guide

How often should I take ivermectin? Expert Recommendations

Clinical analysis and evidence-based reference guide covering indications, administration protocols, and safety parameters.

Dosing & Administration Guide

How Long Does Ivermectin Take to Work? Timelines Explained

Clinical analysis and evidence-based reference guide covering indications, administration protocols, and safety parameters.

Dosing & Administration Guide

Should you take ivermectin with food? Dosage Tips for Best Results

Clinical analysis and evidence-based reference guide covering indications, administration protocols, and safety parameters.

Pharmacokinetic Profiles, Milligram-per-Kilogram Calibrations, and Food-Effect Dynamics

Ivermectin dosing operates on weight-based pharmacokinetics ($mu ext{g/kg}$ body mass) rather than static tablet administration. For adult and pediatric patients weighing $ge 15 ext{ kg}$, the standard single oral dose for uncomplicated intestinal strongyloidiasis is approximately $200 ext{ }mu ext{g/kg}$, whereas onchocerciasis protocols typically utilize $150 ext{ }mu ext{g/kg}$ administered at 6- to 12-month intervals. Achieving correct systemic exposure is critical: subtherapeutic levels risk treatment failure and pathogen persistence, whereas excessive dosage can overwhelm P-glycoprotein blood-brain barrier defenses.

Food intake significantly influences oral bioavailability. Administering ivermectin with a high-fat meal increases peak plasma concentrations ($C_{max}$) and area under the curve ($ ext{AUC}$) by approximately 2.5-fold compared to fasting conditions. While fasting administration is standard for luminal gastrointestinal helminths to maintain drug presence within the gut, dermatological conditions (such as scabies and demodex) may benefit from enhanced systemic absorption under medical supervision. The evaluation matrix below establishes reference dosing parameters.

Indication / SubjectStandard Dosage MetricAdministration Schedule & Timing Parameters
Strongyloidiasis (Human)~200 mcg/kg body weightSingle oral dose with water; follow-up stool examinations at 1 and 3 months
Onchocerciasis (Human)~150 mcg/kg body weightSingle oral dose repeated every 6 to 12 months until microfilariae clear
Sarcoptic Scabies (Human)200 mcg/kg body weightTwo doses administered exactly 7–14 days apart to eradicate newly hatched nymphs
Feline Ectoparasites (Veterinary)200–300 mcg/kg body weightStrict veterinary calculation; highly toxic in low-weight kittens
Canine Heartworm Prophylaxis6 mcg/kg body weightStrictly micro-dosed monthly tablet; fatal if dosed at livestock anthelmintic levels

Topic Directory & Specialized Research Chapters

Frequently Asked Questions & Expert Guidance

Should ivermectin tablets be taken with meals or on an empty stomach?

For intestinal parasites like strongyloidiasis, clinical guidelines recommend taking tablets with water on an empty stomach (at least 2 hours before or after eating). For tissue-dwelling parasites, taking with food increases absorption, but must be directed by a physician.

How long does ivermectin remain active in human blood plasma?

The plasma elimination half-life of ivermectin in healthy adults averages 16 to 18 hours. However, active lipophilic metabolites concentrate in adipose and dermal tissues, exerting prolonged antiparasitic action over several days.

What are the dangers of daily ivermectin administration?

Approved human dosing relies on single doses or pulses separated by 7 to 14 days. Daily continuous dosing leads to hepatic bioaccumulation, neurotoxicity (ataxia, confusion, visual disturbances), and potentially fatal metabolic derangement.

Editorial & Peer Review Standard: Curated by the Evidence-Based Antiparasitic Pharmacology & Clinical Standards Desk. Sourced from primary peer-reviewed literature, WHO Model Formulary guidelines, and FDA/EMA statutory databases.

Notice: This educational resource models published peer-reviewed pharmacology literature and regulatory codes for informational and planning purposes only. It does not provide certified medical or veterinary advice. For clinical diagnoses, prescription authorization, and individualized treatment protocols, consult an actively licensed healthcare professional or veterinarian in your jurisdiction.
75 posts